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Venom-derived peptides constitute a unique source of drug prototypes for the pain management. Many
of them can modulate voltage-gated calcium channels that are central in the processing of pain sensa-
tion. PhTx3-4 is a peptide isolated from Phoneutria nigriventer venom, which blocks high voltage-
activated calcium channels with low speciﬁcity, thereby leading to neuroprotection in models of
ischemia in vitro. The aim of the present work was evaluating the potential of intrathecal PhTx3-4 in the
reversal of different nociceptive states in mice, furthermore assessing the potential of PhTx3-4 in trig-
gering motor side effects. We found that bellow 100 pmol/site, PhTx3-4 did not cause major motor side
effects. By comparison, u-conotoxin MVIIA and u-conotoxin MVIIC triggered motor side effects at the
doses of 10 and 100 pmol/site, respectively. Also, PhTx3-4 (30 pmol/site) caused no signiﬁcant alterations
in the forced locomotor activity test (rotarod) and in the exploratory activity test (versamax). In a model
of inﬂammatory persistent pain (formalin test), PhTx3-4 reversed nociceptive behavior both pre or post-
administered, although this effect was observed only at the inﬂammatory phase of the test and not at the
neurogenic phase. Comparatively, u-conotoxin MVIIC was effective only when post-administered in the
formalin test. Nonetheless, PhTx3-4 treatment was devoid of action in acute nociceptive thermal model
(hotplate test), whereas morphine showed efﬁcacy in this test. Efﬁcacy of PhTx3-4 in the formalin test
was associated with inhibition of formalin-induced glutamate release in the cerebrospinal ﬂuid. PhTx3-4,
but not u-conotoxin MVIIC, reversed NMDA-induced nociceptive behavior indicating a putative role of
PhTx3-4 at ionotropic glutamate receptors. Finally, we observed efﬁcacy of PhTx3-4 in ameliorating
mechanical hypersensitivity induced by paw incision, a post-operative and more clinically relevant pain
model. Taken together, our data show that PhTx3-4 possesses antinociceptive effect in different models
of pain in mice, suggesting that this toxin may serve as drug prototype for pain control.
© 2015 Elsevier Ltd. All rights reserved.squisa da Santa Casa, 590,
zil.
ro-Junior).1. Introduction
Ion channels are strikingly and commonly related to the new
drug discovery process (Waszkielewicz et al., 2013). Subtype spe-
ciﬁc modulation of calcium channels, for example, has emerged as a
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2004). In this scenario, animal toxins constitute one of the richest
sources of new molecules. These toxins can control and modulate
ion channels, especially calcium permeable channels, (Bourinet
et al., 2014; Hogg, 2006) providing an invaluable new arsenal of
drug prototypes.
Phoneutria nigriventer's venom has a cocktail of toxins that af-
fects ion channels (Gomez et al., 2002, 2014). The neurotoxic pool,
known as PhTx3 (Cordeiro Mdo et al., 1993), contains six peptides,
PhTx3-1 to PhTx3-6, with the last one being recently renamed
Pha1b. Among them, PhTx3-3, PhTx3-4 and Pha1b are capable of
inhibiting voltage gated calcium channels (VGCC's) with different
potencies and speciﬁcities (Dos Santos et al., 2002; Leao et al.,
2000; Vieira et al., 2005). Among these three toxins, PhTx3-3 and
Pha1b were shown to control acute and persistent pain states in
rodents (Dalmolin et al., 2011; Souza et al., 2008). PhTx3-3 toxin
was effective in the reversal of mechanical allodynia produced by
both sciatic nerve injury and streptozotocin-induced neuropathy in
doses at least 10 times lower than those capable of impairing motor
function (Dalmolin et al., 2011). Pha1b toxin is, to date, the most
well characterized peptide with antinociceptive action from
P. nigriventer venom. Previous studies in rodents have shown that
this toxin has an antinociceptive potential in models of acute and
persistent pain, including neuropathic, visceral, surgical, inﬂam-
matory and cancer painmodels (Castro-Junior et al., 2013; de Souza
et al., 2013; Diniz et al., 2014; Rigo et al., 2013a, 2013b). It is note-
worthy, however, that Pha1b has a wider therapeutic window
compared to u-conotoxin MVIIA and longer-lasting effects
compared, for example, to morphine (de Souza et al., 2011).
PhTx3-4 toxin is puriﬁed from P. nigriventer venom by a com-
bination of different methods, including gel ﬁltration, FPLC, HPLC,
and mass spectrometry techniques (Cordeiro Mdo et al., 1993;
Rezende et al., 1991). PhTx3-4 blocks N and P/Q voltage gated cal-
cium channels with a similar potency (Dos Santos et al., 2002). R-
type currents can also be inhibited by PhTx3-4, but with lower
potency (Dos Santos et al., 2002). Multiple binding sites appear to
be involved in PhTx3-4 action in the central nervous system. Both
the u-conotoxins GVIA and MVIIC can displace PhTx3-4 from
neuronal cell membranes (Dos Santos et al., 2002). Furthermore,
PhTx3-4 can inhibit glutamate release from cortical synaptosomes,
independent of external calcium inﬂux (Reis et al., 1999). Concur-
rently, glutamate uptake in synaptosomes is also inhibited by
PhTx3-4 (Goncaves et al., 2011), suggesting an alternative role for
this toxin on glutamate transporters, in addition to VGCC's.
Central inhibition of neurotransmitter release by PhTx3-4 has
been proven to have beneﬁcial clinical applications. Inhibition of
glutamate release caused by PhTx3-4 prevents neuronal cell death
following the in vitro induction of ischemia in the hippocampus
(Pinheiro et al., 2009) as well as in the retina (Agostini et al., 2011).
Until now, there have been no studies addressing the anti-
nociceptive potential of PhTx3-4 toxin. Therefore, the aim of the
present work is to evaluate the antinociceptive potential of PhTx3-4
in models of acute and persistent inﬂammatory pain in mice and to
investigate the potential of PhTx3-4 in inducing motor side effects
commonly related to spinal voltage-gated calcium channel
inhibition.
2. Materials and methods
2.1. Drugs
Native PhTx3-4 was puriﬁed from the venom of the spider P.
nigriventer by a combination of gel ﬁltration, reverse phase FPLC/
FPLC and ion exchange HPLC, as previously described (Cordeiro
Mdo et al., 1993). PhTx3-4 has a molecular weight of 8449 DA,and its amino acid sequence is SCINVGDFCDGKKDCCQCDRD-
NAFCSCSVIFGYKTNCRCEC, accession number NCBI P81790. u-Con-
otoxin MVIIA and u-Conotoxin MVIIC were purchased from
Latoxan (Valence, France). Morphine sulfate was purchased from
Laboratorio Cristalia (Sao Paulo, Brazil). The stock solutions of the
drugs were prepared in PBS in siliconized plastic tubes, maintained
at 18 C and diluted to the desired concentrations just before use.
Glutamate dehydrogenase type II (EC 1.4.1.3), NADPþ, glutamic and
MK801 were obtained from Sigma (MO, USA). All other reagents
were of analytical grade.
2.2. Animals
Male adult Swiss mice (25e35 g) were acclimatized in the lab-
oratory for at least 2 h before testing, and they were used only once
throughout the experiments. While in the home cage environment,
the animals were allowed free access to water and food. The room
temperature was maintained at 22 ± 1 C, and the room illumi-
nation was on a 12/12 h light/dark cycle. The experiments were
carried out in accordance with the current guidelines for the care of
laboratory animals and the ethical guidelines for experiments in
conscious animals (Zimmermann, 1983) and were authorized by
the Ethics Committee of the Federal University of Minas Gerais,
protocol 347/2012.
2.3. Intrathecal (i.t.) injections
The i.t. injections were performed in accordance with the
method previously described (Hylden and Wilcox, 1980). Brieﬂy, a
volume of 5 mL was administered with a 28-gauge needle con-
nected to a 10-mL Hamilton micro syringe while the animal was
lightly restrained to maintain the position of the needle. Puncture
of the dura was indicated behaviorally by a slight ﬂick of the tail.
Behavioral evaluation was performed blindly with respect to drug
administration.
2.4. Hot-plate test
The hot-plate test was used to measure acute thermal noci-
ception according to the previously described method (Macdonald
et al., 1946), with minor modiﬁcations. Mice were placed into a
square chamber with a 24-cm side on the heated surface
(55 ± 0.5 C). The nociceptive response was measured as the time
latency between placement and the licking of the paws or jumping.
The cut-off time was 30 s to avoid tissue damage. The animals were
administered by the intrathecal (i.t.) routewith vehicle (phosphate-
buffered saline, PBS, 5 mL/site), PhTx3-4 (30 pmol/site),u-conotoxin
MVIIC (30 pmol/site) or morphine (3000 pmol/site). The hot-plate
test was conducted between 0.25 and 4 h following drug treatment.
2.5. Formalin test
Acute neurogenic and persistent inﬂammatory nociception
were evaluated using the formalin test (Dubuisson and Dennis,
1977), with minor modiﬁcations. Twenty microliters of saline
containing 2.5% formalin was injected subcutaneously into the
right dorsal hind paw. The mice were immediately placed in a
polycarbonate box positioned in front of a mirror for behavioral
observations. The nociceptive behavior was quantiﬁed by counting
the time spent licking, ﬂinching and lifting the injected hind paw.
The measurements were taken in two phases: the ﬁrst phase
(neurogenic) was evaluated during the period from 0 to 5 min and
the second phase (inﬂammatory) from 15 to 30 min after formalin
injection. Intrathecal administration of the test agents was per-
formed using a 10-mL micro syringe-containing vehicle (PBS),
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or u-conotoxin MVIIC (0.3e30 pmol/site). For all of the tested
drugs, the volume in the micro syringewas set at 5 mL. To assess the
preventive antinociceptive action, the drugs were administered
0.25, 0.5, 1, 2, or 4 h before formalin (2.5%) injection. To access the
curative antinociceptive action, the drugs were injected 10 min
after the formalin injection.2.6. Incisional pain test
This procedurewas conducted according to amethod previously
described by Pogatzki and Raja (Pogatzki and Raja, 2003). The mice
were anesthetized with halothane. After the antiseptic preparation
of the right hind paw, a 5-mm longitudinal incision was made with
a no.11 blade through the skin and fascia of the plantar foot. The
incisionwas initiated 2 mm from the proximal edge of the heel and
extended toward the toes. The underlying muscle was elevated
using curved forceps, leaving themuscle origin and insertion intact.
The skin was joined with a single mattress suture of 6-0 nylon.
Nociception was evaluated in response to von Frey ﬁlaments, as
described in the next section. To evaluatewhether the tested agents
could retrieve an already ongoing nociceptive process, distinct
groups of mice received PhTx3-4 (3 pmol/site), u-conotoxin-MVIIC
(3 pmol/site), MK801 (30 nmol/site) or vehicle (PBS, 5 mL/site)
10min after the plantar incision. The response to von Frey ﬁlaments
was conducted 0.25, 0.5, 1, 2 and 4 h after treatment with the
agents.2.7. Response to von Frey ﬁlaments
The measurement of the mechanical paw withdrawal threshold
was carried out using the up-and-down paradigm, as described
previously by Chaplan et al. (1994), with minor modiﬁcations.
Brieﬂy, mice were ﬁrst acclimatized (1e2 h) in individual clear
Plexiglas boxes on an elevated wire mesh platform to allow access
to the plantar surface of the hind paws. Von Frey ﬁlaments of
increasing stiffness (0.02e1.4 g) were applied to the hind paw
plantar surface of the animals with a pressure high enough to bend
the ﬁlament. The absence of a paw lift after 5 s led to the use of the
next ﬁlament with increasingweight, whereas a paw lift indicated a
positive response and led to the use of the next weaker ﬁlament.
This paradigm continued for a total of 6 measurements, including
the one before the ﬁrst paw-lifting response or until 4 consecutive
positive or 4 consecutive negative responses occurred. The 50%
mechanical paw withdrawal threshold (PWT) response was then
calculated from the resulting scores, as previously described
(Dixon, 1965). The PWT was expressed in grams (g) and was eval-
uated before and after plantar incision as well as after i.t. injection
of PhTx3-4 or other agents. A signiﬁcant decrease in 50% PWT (g)
compared to baseline values was considered to be mechanical
allodynia.2.8. Spontaneous nociception induced by NMDA
This procedure was conducted as previously described by Urca
and Raigorodsky (1988). Mice received, by intrathecal injection,
N-Methyl-D-Aspartic acid (NMDA) (3 nmol/site). The reaction time
was counted as the nociceptive behavior indicated by the time
spent biting the tail and hindlimbs or scratching animal's ﬂank
right after the NMDA injection. The reaction time was recorded for
3 min. To investigate the effect of the agents, PhTx3-4 (3e30 pmol/
site) or the NMDA receptor antagonist, MK-801 (30 nmol/site),
were co-injected with NMDA.2.9. Measurements of the cerebrospinal ﬂuid (CSF) glutamate levels
These tests were conducted on the animals that were previously
submitted to the formalin test. They received PhTx3-4 (30 pmol/
site), u-conotoxin MVIIC (30 pmol/site), or PBS 9 min after formalin
injection (post-treatment). The mice were killed with halothane
30 min after formalin injection, and the CSF was extracted by the
cistern magna puncture technique. Glutamate measurement was
performed enzymatically by measuring the increase in the ﬂuo-
rescence (excitation wavelength set at 360 nm and emission
wavelength at 450 nm) due to the production of NADPH in the
presence of glutamate dehydrogenase and NADPþ (Nicholls et al.,
1987). To start the assay, NADPþ (1.0 mM) and glutamate dehy-
drogenase (50 U) were added to the CSF samples, and the emitted
ﬂuorescence was measured during 10 min in a Shimadzu RF-
5301PC spectroﬂuorometer. The glutamate levels are directly
related to the emitted ﬂuorescence levels and were normalized to
the maximum ﬂuorescence produced by the addition of L-glutamic
acid (2.5 mM) to the cuvette.
2.10. Evaluation of adverse effects
Central administration of toxins that block VDCC's, usually
elicits the development of gross behavioral adverse effects,
including tail serpentine-like movements, whole-body shaking,
muscle weakness and paralysis (Malmberg and Yaksh, 1994). These
effects were observed in the testedmice from 15min until 3 h post-
i.t. injection of PhTx3-4 (1e300 pmol/site), u-conotoxin MVIIC
(0.3e300 pmol/site), u-conotoxin MVIIA (0.3e100 pmol/site) or
vehicle. Doses of toxins are based mainly in Souza et al. (2008). To
evaluate muscular weakness, the animals were submitted to a
righting reﬂex test, according to Luvisetto et al. (2006), which
consisted of placing the mouse horizontally on its back and
recording, with a stopwatch, the time needed to regain the upright
position. The animals were considered weak when they required
over 3 s to regaining the upright position (Dalmolin et al., 2011).
The forced locomotor activity test was performed in the rotarod
apparatus, as described previously (Dunham and Miya, 1957), with
minor adaptations. One day prior to the toxin side effect assess-
ment, the animals were subjected to one session of training in the
rotarod apparatus. On the day of the experiment, 30 pmol/site of
PhTx3-4 or MVIIC was i.t.-administered, and 5 min later, the ani-
mals were placed in the rotarod (3.7 cm in diameter, 8 rpm). During
a 4-min period, we counted the number of falls and recorded the
ﬁrst fall latency.
The exploratory activity of the mice was measured in a Versa-
Max Legacy Open FieldeLocomotor Activity chamber (Omnitech
Electronics, Inc., Columbus, OH, USA) under bright illumination. To
evaluate the effects of PhTx3-4 (30 pmol/site), u-MVIIC (30 pmol/
site) or vehicle on locomotor behavior the mice were placed in the
activity monitoring chambers (20  20  12 cm). The mice were
evaluated for locomotor activity for 5 min periods at 15 and 60 min
after i.t. injection of the agents. The horizontal exploratory activity
was quantiﬁed in centimeters (cm). The vertical exploratory ac-
tivity was also quantiﬁed as the “rearing” time in seconds (sec). For
these assays, each mouse was only used once.
2.11. Statistical analysis
Statistical analysis was carried out by Student's t-test, Fisher's
exact test, or 1-way or 2-way analysis of variance followed by
StudenteNewmaneKeuls’, Bonferroni, KruskaleWallis (non para-
metric) and Dunn's post-tests when appropriate. P values < 0.05
were considered signiﬁcant. When possible, the ID50 values were
calculated by nonlinear regression by a dose-response equation
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individual experiments using GraphPad Software 4.0 (GraphPad, La
Jolla, CA, USA); these were reported as the geometric means
accompanied by their respective 95% conﬁdence limits.
3. Results
Before conducting tests with PhTx3-4 in models of acute and
persistent inﬂammatory pain in mice, we aimed to assess the po-
tential of this toxin in the development of the gross behavioral side
effects that are usually elicited by the central administration of
VDCC blockers (Table 1). Intrathecal injection of PhTx3-4
(1e300 pmol/site) caused no observable effects on serpentine tail
movements or body shaking. However, weakness and paralysis
were observed, starting at a dose of 100 pmol/site. By comparison,
MVIIC also elicited weakness and paralysis at 100 pmol/site;
however, a dose of 300 pmol/site of this toxin triggered weakness
and paralysis in all of the tested animals (p < 0,01). The i.t. injection
of the selective N-type channel blocker u-conotoxin MVIIA was
unable to cause weakness or paralysis at any of the doses tested.
However, this toxin triggered serpentine tail movements and body
shaking at doses of 3 and 10 pmol/site, respectively. From the data
observed in these tests, we decided to use PhTx3-4 at the dose of
30 pmol/site to assess other motor side effects.
Accordingly to the previous data, intrathecal administration of
higher doses of PhTx3-4 induced signs of toxicity, such as weakness
and ﬂaccid paralysis. We therefore decided to test PhTx3-4 and u-
conotoxin MVIIC in the forced locomotor activity test as well as the
exploratory activity test. We used the higher dose of both PhTx3-4
and u-conotoxin MVIIC, which were devoid of gross behavior side
effects (Table 1). The data are presented in Fig. 1. PhTx3-4 (30 pmol/
site) and u-conotoxin MVIIC (30 pmol/site) were unable to signif-
icantly change the latency to the 1st fall (Fig. 1A) and number of
falls (Fig. 1B) at any of the intervals tested (0.25 h and 1 h). PhTx3-4
caused no major changes in the exploratory activity test as deter-
mined by the lack of alteration in the rearing time (Fig. 1C) and total
horizontal distance (Fig. 1D). However, u-conotoxin MVIIC
(30 pmol/site) led to a greater total distance compared to PBS
during the tested time intervals (0.25 h and 1 h, Fig. 1D).
Next, we assessed the effects of PhTx3-4 in a model of persistent
inﬂammatory pain in mice, the formalin model (Fig. 2). Pre-Table 1
Side-effects assessment of the intrathecal administration of Tx3-4, MVIIC or MVIIA in m
Drug Dose (pmol/site) Serpentine tail movement
PBS NA 0/6
Tx3-4 1 0/6
3 0/6
10 0/5
30 0/6
100 0/6
300 0/6
MVIIC 0,3 0/6
1 0/6
3 0/6
10 0/6
30 0/6
100 0/6
300 0/6
MVIIA 0,3 0/6
1 0/6
3 1/6
10 3/6
30 4/6
100 5/6*
The data are expressed as the number of animals showing behaviors/total injected anim
control (PBS-treated) groups. NA, not applicable.treatment with PhTx3-4 (30 pmol/site) produced antinociception
in the inﬂammatory phase of the formalin test. Statistical signiﬁ-
cance for this effect was observed when PhTx3-4 was administered
at 0.5 h (p < 0.05) and 1.0 h (60 ± 8% of inhibition; p < 0.01) pre-
vious to the formalin test. There was no observable antinociceptive
effect for u-conotoxin MVIIC (30 pmol/site) in either the neuro-
genic or inﬂammatory phase of the formalin test.
We further investigated the effects of pre-treatment with
PhTx3-4 in amodel of acute thermal pain: the hot plate test. PhTx3-
4 and u-conotoxin MVIIC (both at 30 pmol/site) were unable to
signiﬁcantly change the withdrawal latency in the hot plate test at
any time following administration of the agents (Fig. 3). On the
other hand, morphine (3000 pmol/site), a positive control for this
test, produced antinociceptive responses that started from 1 h after
administration (60 ± 19%; p < 0.001 compared to PBS) and lasted
for 1 h (Fig. 3C).
Additionally, we investigated the capacity of PhTx3-4 to reverse
an ongoing nociceptive state. Intrathecal administration of PhTx3-4
(3e30 pmol/site), 9 min after formalin injection, reduced the
duration of the nociceptive behavior (Fig. 4A). Inhibition of the
nociceptive response by PhTx3-4 was dose-dependent and reached
statistical signiﬁcance at 30 pmol/site. At this dose, the inhibition
was 60 ± 9%. Intrathecal administration of u-conotoxin MVIIC
(0.3e30 pmol/site) 9 min after the formalin injection was also able
to reduce the duration of the nociceptive behavior (Fig. 4B). The
inhibition caused by u-conotoxin MVIIC at 30 pmol/site was
48 ± 12%.
As previously described (Malmberg and Yaksh, 1994), formalin
injection into the paw increased the glutamate levels in the cere-
brospinal ﬂuid (CSF). Next, we decided to test if the PhTx3-4-
induced antinociceptive effect in the formalin test is associated
with the control of glutamate release into the cerebrospinal ﬂuid.
The data are shown in Fig. 5. Treatment with PhTx3-4 (30 pmol/
site) reduced the glutamate levels in the CSF to 40 ± 9% compared
to the PBS-treated animals (P < 0.05), whereas u-conotoxin MVIIC
treatment tended to reduce the glutamate levels, although the
result did not reach statistical signiﬁcance (74 ± 14% of the PBS
group).
Thereafter, we investigated whether PhTx3-4 could reverse the
nociceptive behavior induced by in situ activation of NMDA re-
ceptors. As previously observed by other authors (Urca andice.
Body shake Weakness Paralysis
0/6 0/6 0/6
0/6 0/6 0/6
0/6 0/6 0/6
0/5 0/5 0/5
0/6 0/6 0/6
0/6 2/6 4/6
0/6 3/6 4/6
0/6 0/6 0/6
0/6 0/6 0/6
0/6 0/6 1/6
0/6 0/6 0/6
0/6 0/6 0/6
0/6 1/6 2/6
0/6 6/6** 6/6**
0/6 0/6 0/6
0/6 0/6 0/6
0/6 0/6 0/6
2/6 0/6 0/6
3/6 0/6 0/6
3/6 0/6 0/6
als and were analyzed by Fisher's exact test (n ¼ 5e6). *P < 0.05; **P < 0.01 versus
Fig. 1. Effects of PhTx3-4 and u-conotoxin MVIIC in the forced locomotor activity test and the exploratory activity test. Latency to the ﬁrst fall (A) and the number of falls for the
animals treated with PhTx3-4 and u-conotoxin MVIIC (30 pmol/site) in the forced locomotor activity test (B). Treatments were conducted 0.25 h or 1 h prior to testing. Rearing time
(C) and total distance explored for the animals treated with PhTx3-4 and u-conotoxin MVIIC (30 pmol/site) in the exploratory activity test (D). Again, treatments were conducted
0.25 h or 1 h prior to testing. Each bar represents the mean ± S.E.M for A, C and D (n ¼ 7e8 animals). In B, the bar represents the median þ75% interquartile range (n ¼ 7e8
animals).* means p < 0.05 and **p < 0.01 by one way ANOVA followed by the NewmaneKeuls test.
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elicited a characteristic nociceptive behavior, quantiﬁed as the time
spent biting the tail and hindlimbs or scratching the ﬂanks. Data are
shown in Fig. 6. Co-administration of PhTx3-4 and NMDA (Fig. 6A)Fig. 2. Time course of the antinociceptive effect produced by intrathecal pre-treatment of Ph
4.0 h before formalin injection on the neurogenic (A, C) and inﬂammatory (B, D) phases of the
and ***P < 0.001, compared to the PBS group, two way ANOVA followed by the Bonferronidose-dependently reversed the NMDA induced nociceptive
behavior (66.8 ± 10% of inhibition for PhTx3-4 at 30 pmol/site,
P < 0.001 compared to the PBS-treated group). On the other hand,
u-conotoxin MVIIC (Fig. 6B) was unable to inhibit the nociceptiveTx3-4 (30 pmol/site) or u-conotoxin MVIIC (30 pmol/site), administered from 0.25 h to
test in mice. The data are reported as the mean ± SEM for n ¼ 8e9 per group. *P < 0.05
test.
Fig. 3. PhTx3-4, u-conotoxin MVIIC and morphine effects in the hot-plate test in mice. Time courses for the withdrawal latency in the hot-plate test after intrathecal administration
of 30 pmol/site of PhTx3-4 (A), 30 pmol/site of u-conotoxin MVIIC (B) or 3000 pmol/site of morphine (C). Both PhTx3-4 and u-conotoxin MVIIC were devoid of antinociceptive
action in the tested conditions. N ¼ 6e8 per group; *P < 0.05 and ***P < 0.001, compared to PBS at the respective time-points, two-way ANOVA followed by the Bonferroni test.
Fig. 4. Post-treatment effect of PhTx3-4 (3e30 pmol/site) or u-conotoxin MVIIC (0.3e30 pmol/site) 9 min after intraplantar formalin injection. Dose response curves for PhTx3-4
(A) or u-conotoxin MVIIC (B) during the inﬂammatory phase of the formalin test. The data are reported as the mean ± SEM for n ¼ 8e11 per group. *P < 0.05, compared to the PBS
group (one way ANOVA followed by the StudenteNewmaneKeuls test).
Fig. 5. Glutamate levels in the cerebrospinal ﬂuid (CSF) of rats treated with PhTx3-4
(30 pmol/site) or u-conotoxin MVIIC (30 pmol/site) 30 min after formalin injection.
Values are reported as the mean ± SEM of the glutamate concentrations, in pmol/mL, in
the CSF after normalization to the PBS group; n ¼ 3e4 per group. *P < 0.05, compared
to the PBS group (one way ANOVA with KruskaleWallis, non-parametric test, followed
by Dunn's multiple comparison test).
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NMDA receptor antagonist MK801 (30 nmol/site), produced
68.2 ± 7% of the inhibition of the nociceptive behavior (Fig 6A).
Furthermore, we aimed to evaluate the capacity of PhTx3-4 to
reverse an ongoing pain state that is more clinically related to
humans, post-operative nociception. The data are shown in Fig. 7.
Mice that underwent an incision in the paw showed a signiﬁcantly
reduced mechanical threshold compared to the values obtained
before paw incision. Intrathecal PhTx3-4 (3 pmol/site) signiﬁcantly
reversed the mechanical threshold at 0.5 and 1 h following its
administration (maximum retrieval: 80 ± 12% at 1 h, P < 0.001). The
u-conotoxin MVIIC and the NMDA receptor inhibitor MK-801 also
reversed the mechanical hypersensitivity induced by plantar inci-
sion (69 ± 16 and 65 ± 10%, at 0.25 and 1 h, respectively).4. Discussion
In this manuscript, we evaluated, in mice, the antinociceptive
potential of PhTx3-4, a 40 amino acid peptide puriﬁed from the
venom of the “armed” spider P. nigriventer. The present data show
that this toxin is capable of reversing ongoing nociceptive states in
doses that are devoid of motor side effects. Despite the lack of effect
in the hot plate test, PhTx3-4 administered before or after the
nociceptive stimulus was capable of diminishing the nociceptive
behavior induced by plantar formalin injection. This effect was
associated with a reduction in the glutamate levels in the cere-
brospinal ﬂuid. Moreover, NMDA-induced nociceptive behavior
was also attenuated by PhTx3-4. Finally, PhTx3-4 was also effective
Fig. 6. NMDA-induced nociceptive behavior. Dose responses for PhTx3-4 (A) or u-conotoxin MVIIC (B) for the Biting and Scratching Time (BST) induced by NMDA. The agents were
co-injected with NMDA by the intrathecal route. The NMDA receptor antagonist MK801 (30 nmol/site) was used as a positive control (shown in A). Each bar represents the
mean ± S.E.M, n ¼ 5e6 animals. **p < 0.01 and ***p < 0.001 compared to the PBS-treated group, one way ANOVA followed by the StudenteNewmaneKeuls test.
Fig. 7. Incisional post-operative nociceptive model. The graph shows the mechanical thresholds in g (Mean ± S.E.M.) from animals before surgery (BS), post-surgery (PS) and after
the treatments indicated in the ﬁgure legend. The treatments were conducted 10 min after surgery and the tests were conducted at the times indicated below the graph. (n ¼ 6e8
animals). #p < 0.05 compared to the BS condition.*, **, *** denotes signiﬁcance levels P < 0.05, 0.01 and 0.001, respectively, compared to animals treated with PBS for each time
interval, one way ANOVA followed by the Newman Keuls test.
J.F. da Silva et al. / Toxicon 108 (2015) 53e61 59in reducing the mechanical hypersensitivity induced by plantar
incision, a model closely related to post-surgical pain in humans.
A considerable arsenal of new ion channels blockers with anti-
nociceptive efﬁcacy has emerged in the last decades, however, the
advancement of these new molecules from pre-clinical to clinical
trials is commonly stopped because of their associated side effects.
Before carrying out tests in models of pain, we addressed the
PhTx3-4 effect on gross behavioral impairments as well as motor
function in mice. These behavioral effects are tightly related to
calcium channel modulation in the spinal cord. Higher doses of
PhTx3-4 induced signals of toxicity, including ﬂaccid paralysis of
the hind paw, weakness and discrete changes in the respiratory
pattern. We suggest that these effects can be related to the inhi-
bition of voltage-gated calcium channels, especially the P/Q-type
that is present in the cell body of motor neurons from the ventral
laminae of the spinal cord; inhibition of these channels can lead to
motor impairment (Malmberg and Yaksh, 1994; Murakami et al.,
2004). However, at 100 pmol/site, a dose in which the toxin pre-
sents higher antinociceptive effect, PhTx3-4 did not cause major
motor deﬁcits, whereasu-conotoxin MVIIA andu-conotoxinMVIIC
caused effects in the exploratory activity test, suggesting a different
role of the u-conotoxins in affecting motor function.
N-type voltage-gated calcium channel blockers can cause
tremor and serpentine tail movements, whereas P/Q channel
blockage leads to ﬂaccid paralysis of the tail and hindpaw
(Malmberg and Yaksh, 1994). PhTx3-4 inhibits both P/Q and N-typecalcium channels (Dos Santos et al., 2002). We believe that a pu-
tative preference for spinal P/Q blockage over N-type blockage is
the reason why this toxin leads to ﬂaccid paralysis of the tail and
hindpaw. It was shown that mice with a loss-of-function mutation
in P/Q calcium channels (the rolling mouse Nagoya) are defective in
motor coordination at the hindpaw (Fukumoto et al., 2009).
The formalin test is a pre-clinical test that is commonly used to
screen for new compounds with analgesic potential (Hunskaar and
Hole, 1987; McNamara et al., 2007). Nociceptive behavior triggered
by formalin injection elicits a biphasic behavior. The ﬁrst phase,
called the neurogenic phase, is mainly due to direct stimulation, by
formalin, of primary afferent ﬁbers. The second phase, called the
inﬂammatory phase, is more persistent than the ﬁrst and is asso-
ciated with the release of inﬂammatory mediators and afferent C
ﬁber activation (Ji and Woolf, 2001; Tjolsen et al., 1992; Vanegas
and Schaible, 2004). We could not observe efﬁcacy for PhTx3-4
and u-conotoxin MVIIC in the neurogenic phase of the formalin
test at a dose of 30 pmol/site. According to previously descriptions,
N-type blockers are capable of inhibiting the neurogenic phase in
the formalin test; however they induced this inhibition at doses
higher than those required to inhibit the inﬂammatory phase (Diaz
and Dickenson, 1997; Malmberg and Yaksh, 1994). Therefore, the
lack of inhibition of the neurogenic phase can be attributed to an
insufﬁcient dosage of the toxins. On the other hand, PhTx3-4, but
not u-conotoxin MVIIC, when pre-administered, inhibited noci-
ceptive behavior in the inﬂammatory phase. However, both PhTx3-
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when they were applied following the formalin stimulus. Although
it is well established that the blockage of N-type and P/Q type
calcium channels can ameliorate nociception in the inﬂammatory
phase of the formalin test (Diaz and Dickenson, 1997; Malmberg
and Yaksh, 1994), it is noteworthy that such efﬁcacy depends
upon the functional interaction of toxins with the channel. It has
been shown that u-conotoxins interact with N-type calcium
channels by preferentially binding the inactivated form of those
channels (Stocker et al., 1997). We suggest that the efﬁciency of
MVIIC, when administered after the nociceptive stimulus, is due to
a putative higher proportion of inactivated calcium channels when
formalin is already administered, leading to a higher fraction of the
channels inhibited by MVIIC in this condition. We hypothesize that
the afﬁnity of PhTx3-4 for the channel is independent of the
channel state, thereby the inhibition caused by PhTx3-4 occurs
regardless if the channel is activated or inactivated, explaining thus
the efﬁcacy of the toxin either pre or post administrated in the
formalin test. However, new experiments are necessary to properly
address this question.
Interestingly, both PhTx3-4 and MVIIC were inefﬁcient at
increasing the latency to paw withdrawal in the hot plate test. This
test represents a model of acute thermal pain without the occur-
rence of tissue injury. Although PhTx3-4 was devoid of anti-
nociceptive efﬁcacy in this test, this result indicates that this toxin
does not interfere with the protection against thermal sensation,
which is important for the preservation of tissue in living organ-
isms. Pha1b, another calcium channel blocker toxin from the PhTx3
pool of P. nigriventer venomwas capable of increasing the latency in
the hot plate test (Souza et al., 2008). However, in that work, the
authors applied toxin at 200 pmol/site, which is higher than the
dose tested for PhTx3-4 (30 pmol/site). As we observed previously,
doses of PhTx3-4 higher than 100 pmol/site led to the appearance
of motor side effects, sowe decided to not test these higher doses in
the hot plate model.
The release of pro-nociceptive neurotransmitters, such as
glutamate, is tightly controlled by functional N-type channels in the
spinal cord (Diniz et al., 2014; Souza et al., 2008). In agreement with
this, our data showed that subarachnoid glutamate overspill,
induced by formalin, was signiﬁcantly reduced by PhTx3-4 pre-
administration. However, u-conotoxinMVIIC was unable to reverse
this process. The lack of speciﬁcity of u-conotoxin MVIIC to distinct
high-voltage calcium channel subtypes may account for the
absence of effect in this assay. Moreover, given that PhTx3-4 is also
a nonspeciﬁc inhibitor of calcium channels, these data suggest that
the antinociceptive action of PhTx3-4 is not only due to N-type
channel inhibition but is instead associated with action on other
cellular targets distinct from calcium channels. In fact, Reis et al.
(1999) have shown that PhTx3-4 can inhibit a calcium-
independent component of glutamate release, likely by causing
glutamate transporter inhibition.
To test whether PhTx3-4 could attenuate pain related to the
direct activation of ionotropic glutamate receptors, we used the
model described by Urca and Raigorodsky (1988). Unlike u-con-
otoxin MVIIC, PhTx3-4 was efﬁcient in the inhibition of the noci-
ceptive behavior induced by intrathecal injection of NMDA. This
result suggests that NMDA receptors are also associated with the
PhTx3-4 antinociceptive potential and are consequently involved in
the control of central sensitization, as observed in some persistent
pain states. Notably, a 10-fold lower dose of PhTx3-4 was efﬁcient
in diminishing NMDA-related pain compared to the efﬁcient dose
of PhTx3-4 in the formalin test. Persistent activation of peripheral
nociceptors occurs in several chronic pain states and is responsible
for central sensitization. This process is controlled by the NMDA
receptor function (Ferreira and Lorenzetti, 1994; Haley et al., 1990;Hama and Sagen, 2009). Accordingly, as we have shown, the posi-
tive control MK801, a selective NMDA receptor inhibitor, and
PhTx3-4 attenuated nociception induced by NMDA. Previous
studies have also identiﬁed toxins with antinociceptive potential
related to NMDA inhibition. Conantokin G and T are cone snail-
derived peptides with powerful antinociceptive effects related to
selective NMDA inhibition (Hama and Sagen, 2009; Malmberg
et al., 2003). More experiments are needed, including binding as-
says and electrophysiological recordings, however, to better
address the possible interaction of PhTx3-4 with NMDA receptors.
Finally, we tested PhTx3-4 in the incisional painmodel (Pogatzki
and Raja, 2003). A 10-fold lower dose of PhTx3-4 was able to
reverse mechanical hypersensitivity following paw incision. This
model is useful to mimic a post-operative condition that is
commonly associated with persistent pain states (Brennan et al.,
1996). The antinociceptive effect of u-conotoxin MVIIC showed a
faster onset kinetics compared to PhTx3-4 since the MVIIC reached
statistical signiﬁcance at 0.25 h whereas PhTx3-4 at 0.5 h. The
antinociceptive effect of Tx3-4 at 1 h was more pronounced,
although not signiﬁcantly different, than the u-conotoxin MVIIC
effect. Although PhTx3-4 was more potent in the incisional model
than in the formalin test, the PhTx3-4 effect lasted for no longer
than 1 h, similar to MK801 and u-conotoxin MVIIC.
In summary, we have characterized the PhTx3-4 effects on
mouse models of acute, chemical, and clinically relevant pain.
Although higher doses of PhTx3-4 triggered weakness and paral-
ysis, lower doses did not causes gross behavioral side effects nor
motor impairment. These lower doses were capable of reversing
mechanical hypersensitivity and nociceptive behavior in the
various pain models. Moreover, antinociceptive action was associ-
ated with the reduction of spinal glutamate levels and inhibition of
NMDA-induced pain behavior, thus providing in vivo evidence for
the potential of this toxin to modulate glutamate ionotropic re-
ceptors. It has been shown that the blockage of Ca2þ permeable
channels is pharmacologically useful for treating pain (Bourinet
et al., 2014). Until recently, the synthetic analog of u-conotoxin
MVIIA, Ziconotide, also known as the commercial product Prialt®, is
the only substance derived from animal toxins that is approved for
pain treatment in humans. Improvements in our understanding of
these toxins may lead to important advances in the development of
new therapeutic agents with higher therapeutic windows and
improved efﬁcacy for intractable types of pain.
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